NEXGEL, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
May 13, 2024 at 10:09 pm
Share
NEXGEL, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was USD 1.27 million compared to USD 0.62 million a year ago. Net loss was USD 0.853 million compared to USD 0.814 million a year ago.
Basic loss per share from continuing operations was USD 0.14 compared to USD 0.15 a year ago. Diluted loss per share from continuing operations was USD 0.14 compared to USD 0.15 a year ago.
NexGel, Inc. is a provider of healthcare, beauty, and over-the-counter products, including ultra-gentle, high-water-content hydrogels. It is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. Its Nexgel segment comprises the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania. Its CG labs segment comprises the CG Converting and Packaging, LLC used for the Companyâs converting and packaging business, which is based in Granbury, Texas. Its hydrogel consumer products are marketed under the brand names MedaGel and LumaGel Beauty. Its brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Dermablock. It also specializes in eye and eyelash consumer products.
NEXGEL, INC. 
